Oslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand will provide an update on Hexvix/Cysview following the new bladder cancer guidelines from American Urological Association (AUA) and the Society of Urological Oncology (SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/ Cysview is recommended.
Agenda (CET)
08:30 - 09:05 Q2 presentation by Kjetil Hestdal, President and CEO, and Erik Dahl, CFO
09:05 - 09:15 Break
09:15 - 09:45 Dr. Sia Daneshmand, MD, Associate Professor of Urology (Clinical Scholar); Director of Urologic Oncology, Director of Research and Fellowship Director, USC Institute of Urology at University of Southern California, Los Angeles, USA
09:45 - 10:00 Ambaw Bellete, President, Photocure Inc. and Head, US Commercial Operations
A light snack will be served from 08:00.
The presentations will be live streamed at www.photocure.com. More details will be provided later.
To attend the presentation, please register by sending an email to gfs@photocure.no.
For further information, please contact:
Photocure
Erik Dahl, CFO
Tel: +47 450 55 000, Email: ed@photocure.com
Notes to editors
About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.